ACTRN12623000609651已完成Unknown
An open-label, randomised, three-arm crossover study to examine the comparative pharmacokinetics of ManNAc administered as an oral solution and as two novel oral tablet formulations in healthy adult males
niversity of South Australia0 个研究点目标入组 6 人开始时间: 2023年6月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 59 Years（—）
- 性别
- Male
入选标准
- •1. Male and aged 18-59 years, inclusive.
- •2. Body mass index (BMI) is between 18.0 – 30.0 kg/m^2 with a body weight between 45.0 – 120.0 kg.
- •3. Medically healthy without any clinically significant abnormalities. Health status will be determined by the participant's medical history with specific attention to: (i) drug history, identifying any known drug allergies or drug abuse, (ii) any chronic use of medication, and (iii) a thorough review of body systems (vital signs, electrocardiogram (ECG), physical examination and clinical laboratory tests).
- •4. Adequate venous access on their left or right arm to allow for collection of multiple blood samples.
- •5. Aware of the study procedures and the risks involved, and voluntarily agrees to participate by providing written informed consent.
- •6. Willing and able to understand the study procedures and communicate effectively with study personnel.
排除标准
- •1. History or presence of any medical condition that, in the opinion of the Medical Officer, may pose an unacceptable level of risk to participants or study staff, may interfere with the interpretation of safety data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of ManNAc.
- •2. History of hypersensitivity to ManNAc or ingredients within the formulations or, in the judgment of the Medical Officer, has a condition that places the participant at increased risk for adverse effects.
- •3. Ingestion of an investigational medication or a new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to dosing in Period 1.
- •4. Treated with ManNAc, sialic acid, intravenous immunoglobulin (IVIg), and/or other supplement containing sialic acid (e.g. St. John’s Wort, sialyllactose) within 120 days prior to dosing in Period 1.
- •5. Unable or unwilling to refrain from the use of medications, including complementary therapies and supplements, within 5 half-lives of, or for 24 h prior to dosing (whichever is longer) until completion of all study procedures within each study period.
- •6. Major surgery within 4 weeks prior to the screening evaluation, or planned surgery prior to completion of all study procedures.
- •7. Donation of blood or blood products of 470 mL or greater within 12 weeks prior to dosing in Period 1, and/or unable or unwilling to refrain from donation from the screening evaluation until completion of all study procedures.
- •8. History or current evidence of alcohol abuse and/or unable or unwilling to refrain from alcohol consumption for 24 h prior to dosing until completion of all study procedures in each study period.
- •9. History or current evidence of drug abuse, positive urine drug screen during screening, and/or unable or unwilling to refrain ingestion of drugs of abuse from the screening evaluation until completion of all study procedures.
- •10. Unable or unwilling to refrain from consuming food and/or beverages that contain caffeine or other xanthines (e.g. coffee, tea, cola, energy drinks and chocolate) for 24 h prior to dosing until completion of all study procedures in each study period.
- •11. Unable or unwilling to refrain from the use of tobacco products for 24 h prior to dosing until completion of all study procedures in each study period.
- •12. Unable or unwilling to refrain from food intake from 10 h prior to dosing until the 4 h timepoint in each study period.
- •13. Unable or unwilling to refrain from fluid intake, aside from that given as part of study procedures, from 1 h prior to dosing until the 4 h timepoint in each study period.
- •14. Unable or unwilling to remain seated in an upright position from immediately prior to dosing until the 4 h timepoint in each study period.
- •15. Unable or unwilling to be confined to the UniSA Clinical Trial Facility for 12 hours on the specified study days and/or attend the other study visits.
- •16. Dietary requirements that prevent consumption of the standardised study meals.
- •17. Poor complier or unlikely to attend specified study days.
研究者
相似试验
已完成
1 期
A three-dose study of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) in fasting conditions to determine the difference in absorption when dosed differently in healthy male participantsGNE MyopathyMusculoskeletal - Other muscular and skeletal disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12620001127998niversity of South Australia12
已完成
不适用
A randomized, open-label, three-way crossover clinical trial to compare safety and pharmacokinetic characteristics after single administration of Carol-F Tab, Advil Liqui-Gels and Brufen Tab 200 mg in healthy male volunteersDiseases of the nervous systemKCT0002017Dong-A University Hospital36
尚未招募
不适用
An investigator initiated study to study how well does a newly developed spirometer by Cipla Ltd. work as compared to the spirometer already available in the market.CTRI/2019/08/020738Chest Research Foundation
进行中（未招募）
1 期
A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthmaMedDRA version: 9.1 Level: LLT Classification code 10003553 Term: AsthmaAsthmaEUCTR2007-006249-42-GBAstraZeneca AB
进行中（未招募）
不适用
AMulti-drug resistant tuberculosisMedDRA version: 14.1Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-005492-13-NLJanssen infectious diseases BVBA